RG7834

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

RG7834 是一种高选择性、口服生物可利用的 HBV（HBsAg 和 HBeAg 以及 HBV DNA）抑制剂，在 dHepaRG 细胞中的 IC50 分别为 2.8、2.6 和 3.2 nM。

RG7834 is a highly selective and orally bioavailable inhibitor of HBV(HBsAg and HBeAg and HBV DNA with IC50s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells).

RG7834 ((S)-(+)-64) is a highly selective and orally bioavailable HBV inhibitor, potently inhibits HBV antigens (both HBsAg and HBeAg) and HBV DNA, with IC50s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells.RG7834 has no activity against CYP3A4, CYP2D6, CYP2C9 (IC50s >50 μM) or hERG channel.

RG7834 (4 mg/kg, twice daily for 21 days) shows anti-HBV efficacy in HBV-infected human liver chimeric uPA-SCID mice.RG7834 (2, 14.5 mg/kg, p.o.) exhibits good oral bioavail ability, with a half-life of 4.9 h in mice. Animal Model:HBV-infected human liver chimeric uPA-SCID mice Dosage:4 mg/kg Administration:Twice daily for 21 days Result:Reduced both HBsAg and HBeAg, also decreased serum HBV DNA by 0.6 log10 in mice.

RO 7020322

Microbiology/Virology

HBV

HBeAg|HBsAg|HBV DNA

——

——

2072057-17-9

401.45

C22H27NO6

>98% (HPLC)

DMSO:125 mg/mL (311.37 mM; Need ultrasonic)

CC(C)[C@@H]1CC2=CC(=C(C=C2C3=CC(=O)C(=CN13)C(=O)O)OC)OCCCOC

——

(-20℃)

With Ice Pack

≥ 2 years